A5051430596- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- Esophageal Cancer Research and Treatment
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Radiopharmaceutical Chemistry and Applications
- Immune Cell Function and Interaction
- Angiogenesis and VEGF in Cancer
- Cancer therapeutics and mechanisms
- Brain Metastases and Treatment
- Cancer, Hypoxia, and Metabolism
- Virus-based gene therapy research
- Pancreatic and Hepatic Oncology Research
- Monoclonal and Polyclonal Antibodies Research
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- DNA Repair Mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Ferroptosis and cancer prognosis
University of Oxford
2016-2025
University of California, San Francisco
2025
Churchill Hospital
2015-2024
Oxford University Hospitals NHS Trust
2014-2024
Oxford BioMedica (United Kingdom)
2015-2024
Oxford Biomedical Research
2020-2024
MRC Weatherall Institute of Molecular Medicine
2013-2024
University at Buffalo, State University of New York
2024
University of Wollongong
2024
John Radcliffe Hospital
2010-2023
Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients unresected stage IIIB IV melanoma randomized open-label phase III trial.Patients injectable that not surgically resectable were randomly assigned at two-to-one ratio intralesional or...
Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared chemotherapy, but responses often short-lived. In previous trials, MEK inhibition appeared to be promising this population.
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In United States, has also as adjuvant therapy melanoma on basis recurrence-free overall survival rates were higher than those with placebo in a phase 3 trial. We wanted to determine efficacy nivolumab versus patients resected this randomized, double-blind, trial, we randomly assigned 906 (≥15 years age) who undergoing complete resection stage IIIB, IIIC, or IV receive an...
PURPOSE: : To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) terms of overall survival, progression-free survival (PFS), objective response, safety, to assess health-related quality life (QOL) pharmacokinetics both drugs their metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboximide (MTIC). PATIENTS AND METHODS: Patients were randomized receive either oral at a starting dosage 200 mg/m 2 /d for 5 days every 28 or intravenous (IV) DTIC 250...
High-intensity focused ultrasound (HIFU) provides a potential noninvasive alternative to conventional therapies. We report our preliminary experience from clinical trials designed evaluate the safety and feasibility of novel, extracorporeal HIFU device for treatment liver kidney tumours in Western population. The extracorporeal, ultrasound-guided Model-JC Tumor Therapy System (HAIFU™ Technology Company, China) has been used treat 30 patients according four trial protocols. Patients with...
Purpose Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate is unknown. Patients Methods with ductal adenocarcinoma treated within international, phase III, European Study Group Pancreatic Cancer–3 (version 2) study were included if they had been randomly assigned chemotherapy. Overall analysis was performed on an intention-to-treat basis, retaining patients in their randomized groups, adjusting...
Abstract Purpose: One mechanism of tumor resistance to cytotoxic therapy is repair damaged DNA. Poly(ADP-ribose) polymerase (PARP)-1 a nuclear enzyme involved in base excision repair, one the five major pathways. PARP inhibitors are emerging as new class agents that can potentiate chemotherapy and radiotherapy. The article reports safety, efficacy, pharmacokinetic, pharmacodynamic results first-in-class trial inhibitor, AG014699, combined with temozolomide adults advanced malignancy....
Purpose We report the first-in-human phase Ia study to our knowledge ( ClinicalTrials.gov identifier: NCT01219699) identifying maximum tolerated dose and assessing safety preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)-selective inhibitor. Patients Methods In dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily on a continuous schedule. dose-expansion PIK3CA-wild-type, estrogen...
<h3>Background</h3> Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report final planned analysis of OPTiM, a randomized open-label phase III trial patients with unresectable stage IIIB–IVM1c melanoma. <h3>Methods</h3> Patients were 2:1 to receive intratumoral talimogene or subcutaneous recombinant GM-CSF. In addition overall survival (OS), durable response rate (DRR), objective (ORR), complete responses (CR), safety are also...
To compare the efficacy and tolerability of mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma.This phase II, open-label, multicenter, randomized, parallel-group study examined effect 100 mg oral twice daily 28-day cycles (200 mg/m(2)/d for 5 days, then 23 days off-treatment). The primary endpoint was progression-free survival.Two hundred were...
The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor-positive (ER+), endocrine therapy-resistant breast cancers.To assess the maximum tolerated dose (MTD), safety, and activity of alpelisib, an oral, PI3Kα-specific inhibitor, plus fulvestrant ER+ advanced cancer (ABC).An open-label, single-arm, phase 1b study alpelisib was conducted at 10 centers 5 countries. Participants were 87 postmenopausal women PIK3CA-altered or PIK3CA-wild-type...
The intratumor microenvironment generates phenotypically distinct but interconvertible malignant cell subpopulations that fuel metastatic spread and therapeutic resistance. Whether different microenvironmental cues impose invasive or therapy-resistant phenotypes via a common mechanism is unknown. In melanoma, low expression of the lineage survival oncogene microphthalmia-associated transcription factor (MITF) correlates with invasion, senescence, drug However, how MITF suppressed in vivo...
Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through high affinity T-cell receptor (TCR) binding domain and an anti-CD3 engaging domain, which redirects T cells kill gp100-expressing tumor cells. Here, we report multicenter phase I/II trial of tebentafusp in metastatic melanoma (NCT01211262) focusing on the mechanism action tebentafusp.
A unique collaboration of multidisciplinary experts from the European Dermatology Forum, Association Dermato-Oncology and Organization for Research Treatment Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis treatment, based systematic literature reviews experts' experience. Cutaneous melanomas are excised with 1- 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients tumour thickness ≥1.0 mm or ≥0.8...